Welcome to our dedicated page for Ipsen Sa news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on Ipsen Sa stock.
Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
Ipsen (IPSEY) reported share repurchases under its buy-back programme for the week of 31 August to 4 September 2026.
The company bought a total of 11,270 shares of instrument FR0010259150 at a daily weighted average price of €162.8198. Purchases were executed mainly on 31 August 2026 on XPAR and CEUX, with an additional transaction on 4 September 2026 on XPAR. No shares were repurchased on 1, 2 and 3 September 2026.
Ipsen (IPSEY) reported its monthly share capital and voting rights as of 31 August 2026. The company had 83,814,526 shares outstanding, with a gross total of 132,077,444 voting rights and a net total of 130,818,157 voting rights, in line with French regulatory requirements.
Ipsen (OTC: IPSEY) reported share repurchases under its buy-back programme in compliance with Article 5 of MAR for week 35 of 2026. From 24 to 28 August 2026, Ipsen bought back 3,645 shares on XPAR on 24 August at a daily weighted average price of €161.1922 per share, with no repurchases on the remaining days.
Ipsen (ADR: IPSEY) announced the completion of its acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company. The deal adds navtemadlin, an oral MDM2 inhibitor in Phase III development for myelofibrosis patients who have a suboptimal response to standard first-line therapy ruxolitinib.
The Phase III POIESIS trial is evaluating whether adding navtemadlin to ruxolitinib can improve clinical outcomes versus ruxolitinib alone in intermediate- and high-risk TP53wt myelofibrosis. According to Ipsen, early data suggest the potential to convert suboptimal responses into clinically meaningful responses and possibly provide disease-modifying benefit, subject to successful trials and regulatory approvals.
Ipsen (OTC: IPSEY) published its monthly regulatory disclosure on the share capital and voting rights for Euronext Paris as of 31 July 2026. The company reported 83,814,526 shares outstanding, a gross total of 132,132,996 voting rights and a net total of 130,919,315 voting rights.
Ipsen (OTC:IPSEY) reported weekly activity under its share buy-back programme for 11 August 2026, in line with Article 5 of MAR. The company repurchased a total of 10,000 shares of instrument FR0010259150 across four markets, at a total daily weighted average purchase price of 156.0144 per share.
Ipsen (OTC:IPSEY) reported weekly share repurchases under its buy-back programme for 4–5 August 2026 in accordance with Article 5 of MAR. The company bought back a total of 17,818 shares of ISIN FR0010259150 at a weighted average price of €157.3881 across XPAR, AQEU, TQEX and CEUX.
Ipsen (OTC: IPSEY) reported details of its share buy-back programme for 27–31 July 2026 under Article 5 of MAR. Over this week, Ipsen repurchased 12,313 shares of its stock (ISIN FR0010259150) on the XPAR market at a weighted average price of €159.9296 per share.